222 related articles for article (PubMed ID: 23966299)
1. Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy.
Mascia F; Lam G; Keith C; Garber C; Steinberg SM; Kohn E; Yuspa SH
Sci Transl Med; 2013 Aug; 5(199):199ra110. PubMed ID: 23966299
[TBL] [Abstract][Full Text] [Related]
2. Epidermal EGFR controls cutaneous host defense and prevents inflammation.
Lichtenberger BM; Gerber PA; Holcmann M; Buhren BA; Amberg N; Smolle V; Schrumpf H; Boelke E; Ansari P; Mackenzie C; Wollenberg A; Kislat A; Fischer JW; Röck K; Harder J; Schröder JM; Homey B; Sibilia M
Sci Transl Med; 2013 Aug; 5(199):199ra111. PubMed ID: 23966300
[TBL] [Abstract][Full Text] [Related]
3. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.
Chou LS; Garey J; Oishi K; Kim E
Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S15-22. PubMed ID: 17239286
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib.
McKibbin T; Zhao W; Tagen M; Daw NC; Furman WL; McGregor LM; Geyer JR; Allen JW; Stewart CF
Eur J Cancer; 2010 Jul; 46(11):2045-51. PubMed ID: 20621735
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease.
Takada Y; Matsuo K
Keio J Med; 2012; 61(4):120-7. PubMed ID: 23324306
[TBL] [Abstract][Full Text] [Related]
6. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
Perez-Soler R
Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S7-14. PubMed ID: 17239291
[TBL] [Abstract][Full Text] [Related]
7. A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Zaborowska-Szmit M; Kowalski DM; Piórek A; Krzakowski M; Szmit S
Pharmacol Rep; 2016 Dec; 68(6):1140-1148. PubMed ID: 27588390
[TBL] [Abstract][Full Text] [Related]
8. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
Fujiwara Y; Kiura K; Toyooka S; Takigawa N; Tokumo M; Hotta K; Aoe M; Tabata M; Matsuo K; Date H; Tanimoto M
Lung Cancer; 2006 Apr; 52(1):99-103. PubMed ID: 16503086
[TBL] [Abstract][Full Text] [Related]
9. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
10. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).
Jatoi A; Rowland K; Sloan JA; Gross HM; Fishkin PA; Kahanic SP; Novotny PJ; Schaefer PL; Johnson DB; Tschetter LK; Loprinzi CL
Cancer; 2008 Aug; 113(4):847-53. PubMed ID: 18543329
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies.
Laux I; Jain A; Singh S; Agus DB
Br J Cancer; 2006 Jan; 94(1):85-92. PubMed ID: 16306877
[TBL] [Abstract][Full Text] [Related]
12. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib: an adverse effects profile.
Cersosimo RJ
Expert Opin Drug Saf; 2006 May; 5(3):469-79. PubMed ID: 16610973
[TBL] [Abstract][Full Text] [Related]
14. Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
Kudo K; Hotta K; Bessho A; Nogami N; Kozuki T; Kuyama S; Inoue K; Harita S; Okada T; Gemba K; Fujii M; Takigawa N; Oda N; Tanimoto M; Kiura K
Cancer Chemother Pharmacol; 2016 May; 77(5):1005-9. PubMed ID: 27029623
[TBL] [Abstract][Full Text] [Related]
15. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.
Uhm JH; Ballman KV; Wu W; Giannini C; Krauss JC; Buckner JC; James CD; Scheithauer BW; Behrens RJ; Flynn PJ; Schaefer PL; Dakhill SR; Jaeckle KA
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):347-53. PubMed ID: 20510539
[TBL] [Abstract][Full Text] [Related]
16. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
[TBL] [Abstract][Full Text] [Related]
17. Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment.
Tan AR; Steinberg SM; Parr AL; Nguyen D; Yang SX
Ann Oncol; 2008 Jan; 19(1):185-90. PubMed ID: 17878175
[TBL] [Abstract][Full Text] [Related]
18. EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment.
Huang CL; Yang CH; Yeh KH; Hu FC; Chen KY; Shih JY; Lin ZZ; Yu CJ; Cheng AL; Yang PC
Lung Cancer; 2009 Jun; 64(3):346-51. PubMed ID: 18995924
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor inhibition downregulates
Sierra JC; Asim M; Verriere TG; Piazuelo MB; Suarez G; Romero-Gallo J; Delgado AG; Wroblewski LE; Barry DP; Peek RM; Gobert AP; Wilson KT
Gut; 2018 Jul; 67(7):1247-1260. PubMed ID: 28473630
[TBL] [Abstract][Full Text] [Related]
20. [The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant non-small cell lung cancer patients].
Ma Y; Huang Y; Zhao H; Liu J; Chen L; Wu H; Zhou N
Zhongguo Fei Ai Za Zhi; 2013 Apr; 16(4):203-10. PubMed ID: 23601301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]